Sutro Biopharma, Inc. (STRO) total assets
Sutro Biopharma, Inc. (STRO) had total assets of $173.83M at the end of fiscal 2025 (December 31, 2025). That is 55.1% lower than the $387.21M of fiscal 2024. Figures as of 17 Nov 2026, 23:30 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total assets, fiscal 2025
- $173.83M
- Change on fiscal 2024
- −55.1%
- Growth, 5 years
- −15.1% a year
- Highest on record
- $470.74Mfiscal 2023
- Lowest on record
- $40.77Mfiscal 2017
- Fiscal years on record
- 92017–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Sutro Biopharma, Inc. total assets, in more detail
Over the five fiscal years to 2025 total assets shrank at a compound 15.1% a year. Across the 9 fiscal years on record (2017–2025), the highest was $470.74M in fiscal 2023 and the lowest $40.77M in fiscal 2017.
Total assets by fiscal year
Sutro Biopharma, Inc. total assets, year by year
| Fiscal year | Total assets | Change | Year ended |
|---|---|---|---|
| 2025 | $173.83M | 55.1% down | |
| 2024 | $387.21M | 17.7% down | |
| 2023 | $470.74M | 15.7% up | |
| 2022 | $406.94M | 19.2% up | |
| 2021 | $341.41M | 13.4% down | |
| 2020 | $394.11M | 152.0% up | |
| 2019 | $156.37M | 29.9% down | |
| 2018 | $223.14M | 447.3% up | |
| 2017 | $40.77M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total assets is everything on the balance sheet at the fiscal year-end — cash, receivables, inventory, property, goodwill and the rest.
How to read it
It measures the resources the business has put to work; assets that grow faster than profit mean each new unit of investment is earning less.
Sutro Biopharma, Inc., figure by figure
- Sutro Biopharma, Inc. market cap
- Sutro Biopharma, Inc. revenue
- Sutro Biopharma, Inc. earnings
- Sutro Biopharma, Inc. earnings per share (EPS)
- Sutro Biopharma, Inc. P/E ratio
- Sutro Biopharma, Inc. P/S ratio
- Sutro Biopharma, Inc. P/B ratio
- Sutro Biopharma, Inc. free cash flow
- Sutro Biopharma, Inc. operating margin
- Sutro Biopharma, Inc. dividend
- Sutro Biopharma, Inc. shares outstanding
- Sutro Biopharma, Inc. total debt
- Sutro Biopharma, Inc. cash on hand
- Sutro Biopharma, Inc. return on equity (ROE)
- Sutro Biopharma, Inc. return on invested capital (ROIC)
Sutro Biopharma, Inc. (STRO) overview: price, valuation and scorecard
Sutro Biopharma, Inc. total assets: questions and answers
How large are Sutro Biopharma, Inc.'s total assets?
Sutro Biopharma, Inc. (STRO) had total assets of $173.83M at the end of fiscal 2025 (December 31, 2025). That is 55.1% lower than the $387.21M of fiscal 2024.
What is the growth rate of Sutro Biopharma, Inc.'s total assets?
Over the five fiscal years to 2025 total assets shrank at a compound 15.1% a year.
What are the highest and lowest total assets figures on record for Sutro Biopharma, Inc.?
Across the 9 fiscal years on record (2017–2025), the highest was $470.74M in fiscal 2023 and the lowest $40.77M in fiscal 2017.
How is Sutro Biopharma, Inc.'s total assets calculated?
Total assets is everything on the balance sheet at the fiscal year-end — cash, receivables, inventory, property, goodwill and the rest.
Fiscal years are named for the calendar year they end in.
Learn: total assets
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Sutro Biopharma, Inc. (STRO) total assets”, data as of 17 November 2026. https://funkfolio.com/stock/STRO/total-assets
Underlying data: the company's filings with the SEC and Yahoo Finance.